TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8188467

Group type: EXPERIMENTAL
Intervention: Automated flicker perimeter
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional white/white automated light-sense perimetry
Number of subjects: 130
Study: 3671491

Group type: EXPERIMENTAL
Intervention: Lithium prophylaxis for at least 5 years
Number of subjects: 28
Study: 31418151

Group type: EXPERIMENTAL
Intervention: Basal diet + 1 g/kg of organic mineral mixture
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Basal diet + 0.5 g/kg of organic mineral mixture
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Basal diet + organic mineral mixture (0.5 g/kg and 1 g/kg)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (basal diet without organic mineral mixture)
Number of subjects: 3
Study: 29519219

Group type: EXPERIMENTAL
Intervention: Obese group (manikin modified to emulate a morbidly obese patient)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (standard manikin)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Obese group
Number of subjects: 101
Study: 28088251

Group type: EXPERIMENTAL
Intervention: Lucerastat 1000 mg (SAD study)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Lucerastat 1000 mg b.i.d. (MAD study)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Lucerastat 500 mg (MAD study)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (SAD study)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (MAD study)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Lucerastat (various doses)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Lucerastat (SAD study)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Lucerastat (MAD study)
Number of subjects: 68
Study: 25867075

Group type: EXPERIMENTAL
Intervention: Written asthma action plan
Number of subjects: 407

Group type: COMPARATOR
Intervention: No written instructions other than prescriptions
Number of subjects: 407
Study: 23098249

Group type: EXPERIMENTAL
Intervention: Exposure to thin body pictures (ET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to oversized body pictures (EO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High avoidance (HA) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low avoidance (LA) group
Number of subjects: 0
Study: 21148516

Group type: EXPERIMENTAL
Intervention: Cranberry juice (8 oz of 27% cranberry juice twice daily)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study: 19351303

Group type: EXPERIMENTAL
Intervention: Chemotherapy Symptom Assessment Scale
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale
Number of subjects: 192
Study: 16816060

Group type: EXPERIMENTAL
Intervention: Proactive pregnancy‐tailored telephone counseling
Number of subjects: 442

Group type: COMPARATOR
Intervention: Best-practice brief counseling
Number of subjects: 442
Study: 14643116

Group type: EXPERIMENTAL
Intervention: Ximelagatran (fixed-dose, 36 mg twice daily)
Number of subjects: 3410

Group type: COMPARATOR
Intervention: Warfarin (adjusted-dose, INR 2.0-3.0)
Number of subjects: 3410

Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 3410

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3410
Study: 10688563

Group type: EXPERIMENTAL
Intervention: Feedback plus care management
Number of subjects: 613

Group type: COMPARATOR
Intervention: Feedback only
Number of subjects: 613

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 613
Study: 9484515

Group type: EXPERIMENTAL
Intervention: 6 mg of sumatriptan subcutaneously
Number of subjects: 52

Group type: COMPARATOR
Intervention: 1 mg of dihydroergotamine intramuscularly
Number of subjects: 52
Study: 7524381

Group type: EXPERIMENTAL
Intervention: Prostaglandin- and kininogenesis inhibitors (acelysin and kontrykal)
Number of subjects: 0
Study: 29996689

Group type: EXPERIMENTAL
Intervention: RealConsent program
Number of subjects: 743
Study: 28265715

Group type: EXPERIMENTAL
Intervention: Suvorexant 40/30 mg
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: Suvorexant 20/15 mg
Number of subjects: 1744

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1744
Study: 26710951

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fascia iliaca compartment block (FICB) using probe parallel to the inguinal ligament
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrasound-guided fascia iliaca compartment block (FICB) using probe perpendicular to the inguinal ligament
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (Parallel and Perpendicular)
Number of subjects: 60
Study: 24206075

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 31
Study: 21606213

Group type: EXPERIMENTAL
Intervention: Reactive pulmonary hypertension (mean pulmonary artery pressure > 25 mm Hg, pulmonary capillary wedge pressure > 15 mm Hg, pulmonary vascular resistance > 3 Wood units)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Passive pulmonary hypertension (mean pulmonary artery pressure > 25 mm Hg, pulmonary capillary wedge pressure > 15 mm Hg, pulmonary vascular resistance ≤ Wood units)
Number of subjects: 242

Group type: COMPARATOR
Intervention: No pulmonary hypertension (mean pulmonary artery pressure ≤ 25 mm Hg)
Number of subjects: 242
Study: 19266814

Group type: EXPERIMENTAL
Intervention: Carbamazepine and Flunarizine Hydrochloride
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vitamin B6 and Flunarizine Hydrochloride
Number of subjects: 100
Study: 16783982

Group type: EXPERIMENTAL
Intervention: Male participants blaming the victim more if assaulted by a person of the gender they were normally attracted to.
Number of subjects: 161

Group type: COMPARATOR
Intervention: Female perpetrator
Number of subjects: 161

Group type: COMPARATOR
Intervention: Male perpetrator
Number of subjects: 161
Study: 14568120

Group type: EXPERIMENTAL
Intervention: IFN beta 1a and/or IFN beta 1b
Number of subjects: 42
Study: 10628725

Group type: EXPERIMENTAL
Intervention: Conditioned stimuli (CS +) paired with electric stimulus (UCS)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Conditioning paradigm with EEG recording
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-contingent stimulation (control group)
Number of subjects: 35
Study: 8885806

Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulizer
Number of subjects: 15

Group type: COMPARATOR
Intervention: Jet nebulizer
Number of subjects: 15
Study: 1326348

Group type: EXPERIMENTAL
Intervention: 600 mg rifabutin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 mg rifabutin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 150 mg rifabutin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 75 mg rifabutin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 150 mg rifampicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 mg rifampicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 600 mg rifampicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 mg isoniazid
Number of subjects: 0

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 0
Study: 3885634

Group type: EXPERIMENTAL
Intervention: Postoperative radio- and chemotherapy (group A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Combined longterm chemotherapy (group B)
Number of subjects: 44
Study: 29197785

Group type: EXPERIMENTAL
Intervention: Essential-oils (EO) mouthwash
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 0
Study: 27992435

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF) training, 2 times per week for 12 weeks.
Number of subjects: 52
Study: 24589881

Group type: EXPERIMENTAL
Intervention: Escitalopram (20mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22538805

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 418
Study: 20406930

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study: 16705846

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture combined with Schuell's stimulation and psychological care
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified what the control treatment was)
Number of subjects: 36
Study: 15630195

Group type: EXPERIMENTAL
Intervention: Hydrolyzed Rice Bran (HRB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Water-soluble Rice Bran (RB)
Number of subjects: 50
Study: 11381378

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 39

Group type: COMPARATOR
Intervention: OAA/S scale monitoring (control)
Number of subjects: 39
Study: 9232977

Group type: EXPERIMENTAL
Intervention: Standard recruit training program
Number of subjects: 350

Group type: COMPARATOR
Intervention: Weighted-march activity
Number of subjects: 350
Study: 7679415

Group type: EXPERIMENTAL
Intervention: Intervention group (not specified in the abstract)
Number of subjects: 985

Group type: COMPARATOR
Intervention: Nonenrollment
Number of subjects: 985

Group type: COMPARATOR
Intervention: Dropout
Number of subjects: 985
Study: 3120587

Group type: EXPERIMENTAL
Intervention: fenofibrate
Number of subjects: 36
Study: 31671938

Group type: EXPERIMENTAL
Intervention: Radiotherapy with concurrent temozolomide (75 mg/m2/day) followed by adjuvant temozolomide (150-200 mg/m2/day for 5 days during six 28-day cycles)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Radiotherapy alone (60 Gy in 30 fractions of 2 Gy)
Number of subjects: 84
Study: 31215838

Group type: COMPARATOR
Intervention: SFTSV vaccine
Number of subjects: 0
Study: 27974669

Group type: EXPERIMENTAL
Intervention: Synergy stent
Number of subjects: 185
Study: 23525552

Group type: EXPERIMENTAL
Intervention: Dynamic humeral centring (DHC)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Non-specific mobilisation (Control)
Number of subjects: 69
Study: 24560483

Group type: EXPERIMENTAL
Intervention: Early IUD insertion 1 week after mifepristone
Number of subjects: 156

Group type: COMPARATOR
Intervention: Delayed IUD insertion 4‐6 weeks after medical abortion
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Retained IUDs
Number of subjects: 156
Study: 21859323

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment (baseline) and subgingival debridement (3-month follow-up)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment and supragingival prophylaxis (3-month follow-up)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 134
Study: 19208404

Group type: EXPERIMENTAL
Intervention: Modafinil (up to 300 mg/day for 4 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 32
Study: 17389710

Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR), 20% CR diet (n = 18)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Exercise (EX), 20% increase in energy expenditure through daily exercise (n = 18)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy lifestyle guidelines (HL) (n = 10)
Number of subjects: 48
Study: 16229115

Group type: EXPERIMENTAL
Intervention: New letrozole preparation
Number of subjects: 25
Study: 12145069

Group type: EXPERIMENTAL
Intervention: 0.1% Ropivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.2% Ropivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.1% Bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.2% Bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.1% Ropivacaine and 0.1% Bupivacaine
Number of subjects: 60
Study: 9950311

Group type: EXPERIMENTAL
Intervention: 25% sucrose
Number of subjects: 102

Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 102
Study: 7768250

Group type: EXPERIMENTAL
Intervention: 200-300 mg sustained release diltiazem (200-300 SR) administered once daily
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard diltiazem (D) given three or four times daily
Number of subjects: 144
Study: 2100165

Group type: EXPERIMENTAL
Intervention: Bupranolol 0.25% in an oily solution
Number of subjects: 0
Study: 6259250

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no propranolol)
Number of subjects: 6
Study: 30389476

Group type: EXPERIMENTAL
Intervention: Moderate intensity morning training (Mm)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Morning training (Me)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Morning training
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Vigorous training (Vm)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Vigorous training (Ve)
Number of subjects: 14
Study: 27600367

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 666

Group type: COMPARATOR
Intervention: Placebo (withdrawal)
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Tofacitinib re-treatment (5 mg and 10 mg)
Number of subjects: 666
Study: 24880907

Group type: EXPERIMENTAL
Intervention: Intervention group 1 (n = 66) received 125 ml of ONS twice per day, at 12 and 17 o'clock
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Intervention group 2 (n = 80) received 62 ml of ONS four times a day, at 8, 12, 17 and 20 o'clock
Number of subjects: 234

Group type: COMPARATOR
Intervention: Usual care group (n = 88) offered ONS 125 ml twice per day in between meals
Number of subjects: 234
Study: 23247302

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg twice daily
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 21069516

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg sustained release)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Light treatment (0700 to 0800 hours)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg sustained release) plus Light treatment
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 19164853

Group type: EXPERIMENTAL
Intervention: rTMS (1Hz) to the premotor cortex (PMC) for five consecutive days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Healthy controls received one real rTMS session
Number of subjects: 6
Study: 17213754

Group type: EXPERIMENTAL
Intervention: ERr 731 (1 enteric coated tablet daily for 12 weeks)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo (1 tablet daily for 12 weeks)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: ERr 731
Number of subjects: 109
Study: 15489491

Group type: EXPERIMENTAL
Intervention: Enhanced low vision rehabilitation model (ELVR)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Conventional low vision rehabilitation (CLVR)
Number of subjects: 226
Study: 12402283

Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing (QST)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nerve conduction studies
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sympathetic skin responses
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Vibration thresholds
Number of subjects: 22
Study: 10052571

Group type: EXPERIMENTAL
Intervention: Motion sickness and headache/migraine occurrence during the race
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclical pattern of motion sickness and headache related to menstrual cycle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of male and female subjects
Number of subjects: 0
Study: 7973552

Group type: EXPERIMENTAL
Intervention: Open wound healing technique
Number of subjects: 1208

Group type: COMPARATOR
Intervention: Semi-closed wound healing technique
Number of subjects: 1208
Study: 2502048

Group type: EXPERIMENTAL
Intervention: Peripheral Parenteral Nutrition (PPN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 900915

Group type: EXPERIMENTAL
Intervention: Cefaclor 250 mg orally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cephalexin 250 mg orally
Number of subjects: 0
Study: 31431372

Group type: EXPERIMENTAL
Intervention: Mepitel® Film (MEP)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard care (STD)
Number of subjects: 28
Study: 28635368

Group type: EXPERIMENTAL
Intervention: Autologous stromal/stem cells
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Chondrocytes
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Combined autologous stromal/stem cells and chondrocytes
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3
Study: 1375713

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with collagen sponge implant containing 100 micrograms of antimetabolite (5‐fluorouracil or bleomycin)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil
Number of subjects: 15
Study: 22325668

Group type: EXPERIMENTAL
Intervention: Telephone health coaching (intervention group)
Number of subjects: 64835

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 64835
Study: 20432351

Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: C-PET
Number of subjects: 43

Group type: COMPARATOR
Intervention: FDG-PET
Number of subjects: 43
Study: 18713920

Group type: EXPERIMENTAL
Intervention: 7 mg nicotine patch
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 90
Study: 15918297

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with a monomeric allergoid of Cupressus arizonica pollen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 12917171

Group type: EXPERIMENTAL
Intervention: OBF pneumotonometry
Number of subjects: 10

Group type: COMPARATOR
Intervention: Goldmann tonometry
Number of subjects: 10
Study: 10507957

Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin (6 trials, 2900 participants)
Number of subjects: 9874

Group type: EXPERIMENTAL
Intervention: Aspirin (6 trials, 3119 participants)
Number of subjects: 9874

Group type: COMPARATOR
Intervention: Adjusted-dose warfarin (5 trials, 2837 participants)
Number of subjects: 9874
Study: 8734888

Group type: EXPERIMENTAL
Intervention: Braced ankle
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bare ankle under static conditions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bare ankle under dynamic conditions
Number of subjects: 12
Study: 2010876

Group type: EXPERIMENTAL
Intervention: Information condition (provided information summarizing the psychosocial sequelae of child survivors of cancer)
Number of subjects: 168

Group type: COMPARATOR
Intervention: No information condition (not provided information summarizing the psychosocial sequelae of child survivors of cancer)
Number of subjects: 168
Study: 6352850

Group type: EXPERIMENTAL
Intervention: Home visits by physicians
Number of subjects: 0
Study: 30961342

Group type: EXPERIMENTAL
Intervention: Caffeine citrate prevention group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Caffeine citrate treatment group
Number of subjects: 56
Study: 30508196

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Gefitinib 250 mg once daily
Number of subjects: 120
Study: 28478132

Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study: 26908810

Group type: EXPERIMENTAL
Intervention: Oral valganciclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous ganciclovir
Number of subjects: 0
Study: 24389240

Group type: EXPERIMENTAL
Intervention: Sugar drink
Number of subjects: 185

Group type: COMPARATOR
Intervention: Non-caloric sweetener drink
Number of subjects: 185
Study: 22264885

Group type: EXPERIMENTAL
Intervention: 0.1% fluorometholone 3 times a day (steroid group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Discontinuation of steroid eye drops (no steroid group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 19429734

Group type: EXPERIMENTAL
Intervention: Self-reported adherence-satisfaction with taking medication
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Self-reported adherence-satisfaction with testing blood glucose
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Belief that type 2 diabetes is a serious problem
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Being married
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Cost as a barrier to self-care behaviors
Number of subjects: 253
Study: 18257436

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 19

Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Manipulative therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 19

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 19

Group type: COMPARATOR
Intervention: Adjuvant ultrasound therapy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: NSAIDs, exercise therapy, manipulative therapy, corticosteroid injection, acupuncture
Number of subjects: 19
Study: 16697494

Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (3g/day for 2 months)
Number of subjects: 10
Study: 15477632

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin
Number of subjects: 448

Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 448
Study: 11168226

Group type: EXPERIMENTAL
Intervention: 1:1 mixture of autogenous bone particles and bioactive glass particles (BG-particles)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bone particles only (control side)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both sides (experimental and control)
Number of subjects: 10
Study: 8970755

Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 62

Group type: COMPARATOR
Intervention: Amoxicillin‐clavulanate
Number of subjects: 62
Study: 1451219

Group type: EXPERIMENTAL
Intervention: 2 ml of glucose-free lidocaine 2%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2.5 ml of glucose-free lidocaine 2%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 3 ml of glucose-free lidocaine 2%
Number of subjects: 50
Study: 3881598

Group type: COMPARATOR
Intervention: 10-day treatment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 21-day treatment
Number of subjects: 44